Actively Recruiting

Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
ID06038630

129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function

Led by Bastiaan Driehuys · Updated on 2026-02-04

125

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

B

Bastiaan Driehuys

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying biomarkers from 129Xe gas exchange MRI to understand how they change with different medical interventions. The study focuses on interactions between 129Xe and red blood cells in the lungs. Participants include healthy volunteers and patients with conditions like interstitial lung disease, pulmonary hypertension, acute or chronic pulmonary embolism, anemia, polycythemia, and dyspnea. The study uses hyperpolarized xenon gas inhaled in multiple doses followed by breath holds, alongside oxygen administration. Participants are grouped by treatment: those undergoing transfusion or phlebotomy, patients receiving oxygen for lung-related conditions or healthy volunteers, and those recently diagnosed with acute or chronic pulmonary embolism. Treatments and responses are monitored at baseline and various follow-up points. Participants will undergo MRI scans to measure red blood cell transfer, chemical shifts after oxygen delivery, and changes in red blood cell signal oscillations before and after treatment. The study includes visits up to 3–6 months after interventions to track changes. Researchers also monitor safety and participant adherence throughout the study, which lasts until mid-2028.

CONDITIONS

Brief Title

129Xe MRI Cardiopulmonary

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged over 18
  • Willing and able to give informed consent and follow study visits and procedures
  • Healthy volunteers with no diagnosed lung conditions, no smoking in the past 5 years, and minimal smoking history
  • Patients scheduled for red cell transfusion or therapeutic phlebotomy for blood disorders
  • Patients with physician-diagnosed interstitial lung disease or dyspnea
  • Patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) scheduled for surgery
  • Patients with acute pulmonary embolism within 24-48 hours post-admission
  • Ability to return for follow-up visits 3-6 months after treatment when applicable
Not Eligible

You will not qualify if you...

  • Contraindication to MRI based on screening
  • Pregnancy or breastfeeding
  • Resting oxygen saturation below 90% despite supplemental oxygen
  • Recent respiratory infection within 30 days
  • History of ventricular cardiac arrhythmia or cardiac arrest in the past year
  • Inability to fit into the MRI vest coil
  • Inability to hold breath for at least 10 seconds
  • Inability to follow imaging instructions
  • Medical or psychological conditions posing undue risk or compliance issues

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 5 days around transfusion or phlebotomy; baseline and 1 day for oxygen administration; baseline and 3 to 6 months post-treatment for some groups

Participants undergo MRI scans using hyperpolarized xenon gas and oxygen administration to visualize cardiopulmonary function and assess red blood cell interactions in the lungs.

1 to 3 visits depending on treatment group and timing

Long-term Monitoring

Duration - 3 to 6 months

Participants are followed up to assess changes in red blood cell chemical shifts and oscillation amplitude after treatment.

1 follow-up visit

Trial Site Locations

Total: 1 location

1

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

Loading map...

Research Team

B

Bastiaan Driehuys, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

3

Similar Trials

A Multicenter Prospective Study of Risk Factors in Progressi...

Interstitial Lung Disease

Actively Recruiting

1 location

A Randomized, Double-Blind, Placebo-Controlled, Multicenter ...

Interstitial Lung Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here